Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia

NCT05446831 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

35

Enrollment

OTHER

Sponsor class

Conditions

ITP
Immune Thrombocytopenia

Interventions

DRUG: Baricitinib

Sponsor

Peking University People's Hospital